Context It is unclear whether radioactive iodine (RAI) therapy could improve cancer-specific
survival (CSS) in patients with Hürthle cell carcinoma (HCC) of the thyroid. Objective To …

Background: Hürthle cell carcinoma (HCC) is not typically iodine avid, raising questions
regarding postoperative use of radioactive iodine (RAI). The aims of this study were to …

It is generally believed that Hürthle cell thyroid carcinoma (HCTC) does not accumulate
radioactive iodine (RAI). The aim of our retrospective study was to find out if, after thyroid …

PURPOSE: To determine the role that radiation therapy may have in the management of
resected, unresectable, and metastatic Hürthle cell carcinoma. METHODS AND …

Purpose Radioactive iodine (RAI) is widely used for adjuvant therapy after thyroidectomy,
while its value for thyroid cancer has been controversial recently. The primary objectives of …

Opinion statement Patients with Hürthle cell carcinoma (HCC) of the thyroid often have
aggressive tumors and generally have a worse prognosis than those with papillary or …

Context: Hürthle cell cancer (HCC) of the thyroid remains the subject of controversy with
respect to natural course, treatment, and follow-up. Objective: The objective of the study was …

Hürthle cell carcinoma (HCC) can present either as a minimally invasive or as a widely
invasive tumor. HCC generally has a more aggressive clinical behavior compared with the …

Background Hürthle cell thyroid carcinoma (HCTC) is a rare disease. It is believed that it is
more aggressive than follicular thyroid carcinoma. The aim of our study was to identify …

Background Hürthle cell carcinoma represents approximately 3% of all differentiated thyroid
cancers. The terminology is often confusing, and discrimination between Hürthle cell …